Moving Toward a Personalized Approach to Screening and Management

ACKNOWLEDGEMENT
This activity is supported by an educational grant from Ferring Pharmaceuticals, Inc. and Lilly.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Northwestern University Feinberg School of Medicine and PlatformQ LLC. Northwestern University Feinberg School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Activity
The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Northwestern University Feinberg School of Medicine designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Thursday, January 30, 2014 from 10:00AM to 12:00PM ET
Enduring Material
January 30, 2014 to June 30, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Characterize the data supporting the use of screening and understand the importance of increasing the rate colorectal screening in reducing the incidence of these cancers.
Be informed on the role of neoadjuvant and adjuvant therapy in the management of colorectal cancer and prepared to implement strategies in patients.
Implement complex and effective management strategies for colorectal cancer, incorporating the latest data on targeted biologics and other new therapies in order to optimize outcomes in patients.

TARGET AUDIENCE
This activity is intended for oncologists, radiation oncologists, surgical oncologists, gastroenterologists, pathologists, oncology nurses, advanced practice nurses, and other healthcare professionals, who care for patients with colorectal cancer.

ESTIMATED TIME TO COMPLETE
The activity consists of two sessions, which should take approximately 2.0 hours to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimate that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
In accordance with ACCME Standards for Commercial Support of Continuing Medical Education and the Feinberg School of Medicine's (FSM) disclosure policy for CME activities, all individuals who contribute to the content or the identification / resolution of potential conflicts of interest must disclose any relationship they may have with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients within the preceding 12 months of the activity. Such disclosure is intended to provide participants with sufficient information to evaluate whether any given presentation has been influence by the faculty's relationships(s) or financial interest with said companies.

Presenters: Disclosures:
Al B. Benson III, MD, FACP Research: Amgen, Bayer Healthcare, Genentech, Gilead, Astellas, Novartis, Advanced Accelerator Applications SA
Advisory Board: Precision Therapeutics, Inc., Eli Lilly and Company, Spectrum Pharmaceuticals, Bristol Meyers Squibb, McKinsey, Cleveland Biolabs, Gilead, Bayer Healthcare, Genentech
Consultant: Genomic Health, Inc., National Cancer Institute
DMC: Amgen, Alchemia, Infinity
M. Rosario Ferreira, MD Has nothing to disclose.
John L. Marshall, MD Speaker: Amgen, Genentech, Bayer/Onyx
Research: Amgen, Genentech, Bayer/Onyx
Brandon G. Smaglo, MD Has nothing to disclose.
FSM's CME Leadership  
John X. Thomas, Jr., PhD, Sr. Associate Dean for Medical Education Has nothing to disclose.
Genevieve Napier, CME Director Has nothing to disclose.
Jennifer Banys and Tara Scavelli, CME Project Specialists Have nothing to disclose.
PlatformQ Health, Inc  
Deborah Sharkey, Associate Program Manager Has nothing to disclose.
Alyce Kuklinski, NP, RN, Senior Medical Director Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Northwestern University Feinberg School of Medicine, Office of Continuing Medical Education, by phone: 312-503-8533 or email: nums-cme@northwestern.edu.

For issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com

Personalizing Treatment for Patients with Non-small Cell Lung Cancer (NSCLC)

ACKNOWLEDGEMENT
This activity is supported by an educational grant from Novartis.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Wednesday, June 18, 2014 from 11:00 AM EST - 1:00 PM EST
Enduring Material
The enduring material will be available from June 18, 2014 to December 18, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Summarize current guideline recommendation for prevention, screening and risk assessment of patients with NSCLC
Understand the importance of matching patient characteristics to treatment choice in order to maximize treatment safety, tolerability and patient outcomes
Correlate genetic markers to specific treatment response that can be used to guide treatment selection in patients with NSCLC
Explain why adequate tissue samples and accurate pathology and genetic assessments are critical to treatment decisions-making
Summarize limitations of current treatment options, and the potential targets for new treatments
Summarize efficacy, safety, of emerging treatment options for NSCLC

INTENDED AUDIENCE
This activity is intended for medical and surgical oncologists, oncology nurses and other clinicians involved in the diagnosis and treatment of NSCLC.

ESTIMATED TIME TO COMPLETE
This activity consists of two sessions, which should each take approximately 1 hour to complete, for a total of 2 hours.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Jyoti Patel, MD Has nothing to disclose.
Ajit S. Paintal, MD Speaker's Bureau: Cook Medical, Pfizer
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Bilal Piperdi, MD Speaker's Bureau: Genentech/Roche, Boehringer Ingelheim, Celgene, Merck
Consultant: Genentech/Roche
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.
Alyce Kuklinski, NP, RN, Senior Medical Director Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Advances in the Management of Renal Cell Carcinoma (RCC)

ACKNOWLEDGEMENT
This event is supported by an educational grant from Pfizer, Inc.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 3.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Wednesday, June 25, 2014 from 10:00 AM EST - 3:00 PM EST
Enduring Material
The enduring material will be available from June 25, 2014 to December 25, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Review the mechanisms of action of first-line therapies for RCC, advances in our understanding of RCC pathophysiology, and recently released clinical trial data for these therapies.
Select first-line therapies for advanced and metastatic RCC based on patient clinical characteristics, history of previous treatment, risk factors, co-morbidities, and other relevant considerations.
Assess for and manage treatment-related toxicities effectively when using systemic therapies in patients with advanced or metastatic RCC.
Evaluate recent research findings on molecular genetics and biomarkers that are likely to have future impacts on patient selection, prognostication, and monitoring of treatment efficacy in RCC.

INTENDED AUDIENCE
This activity is intended for medical oncologists, pathologists, oncology nurse practitioners/physician assistants, oncology nurses, and other clinicians involved in the diagnosis and treatment of RCC.

ESTIMATED TIME TO COMPLETE
This activity consists of three sessions, which should each take approximately 1 hour to complete, for a total of 3 hours.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Lauren Harshman, MD Grant/Research: Pfizer, Astellas
Consultant: Pfizer, Dendreon
Sumanta Kumar Pal, MD Consultant: Novartis, Pfizer
Speaker's Bureau: Medivation
Toni Choueiri, MD Consultant: Novartis, Pfizer, Bayer
Laurence Albiges, MD, PhD Grant/Research: Novartis, Pfizer
Consultant: Novartis, Pfizer, Amgen, Sanofi
Naomi B. Haas, MD Consultant: Merck, BMS
Grant/Research: Novartis, GSK
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, MB,BS Speaker's Bureau: Celgene
Grant/Research: GSK
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.
Alyce Kuklinski, NP, RN, Senior Medical Director Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Advancing the Management of Patients with Metastatic Melanoma

ACKNOWLEDGEMENT
This activity is supported by educational grants from Merck & Co., Inc., Genentech, and Bristol-Myers Squibb.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with requirements of the Accreditation Council for Continuing Medical Education through the joint providership of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Internet Activity
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, July 22, 2014 from 11:00 AM EST - 1:00 PM EST
Enduring Material
The enduring material will be available from July 22, 2014 to January 22, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Analyze clinical data evaluating the safety and efficacy of immunotherapies in the treatment of metastatic melanoma
Describe the mechanisms of action of new and emerging immunotherapeutic therapies for metastatic melanoma
Outline the various response patterns to immunotherapy and the related challenges in assessing response
Recognize and manage immune-related adverse events associated with immunotherapies for melanoma
Outline the role of BRAF/MEK/ERK pathway signaling in melanoma, and the development of inhibitors of this pathway
Describe the state of the science with respect to the role of alternate mutations seen in melanoma, such as NRAS, KIT, GNAQ, and GNA11
Outline new research directions in the treatment of metastatic melanoma
Apply individualized treatment strategies for a variety of patients with metastatic melanoma, including a patient with BRAF inhibitor resistance
Manage treatment-related adverse events associated with targeted therapies used in the treatment of metastatic melanoma

INTENDED AUDIENCE
This activity is intended for medical oncologists, dermatologists, surgical oncologists, pathologists, general surgeons, oncology nurse practitioners/physician assistants, oncology nurses, and other clinicians involved in the diagnosis and treatment of melanoma.

ESTIMATED TIME TO COMPLETE
This activity consists of two sessions, which should each take approximately 1 hour to complete, for a total of 2 hours.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Patrick Hwu, MD Has nothing to disclose.
Sapna Patel, MD Grant/Research: Bristol Meyers Squibb, Prometheus
Speaker's Bureau: Merck & Co.
Invited Speaker: Prometheus
Michael Davies, MD, PhD Grant/Research: GlaxoSmithKline, Genentech, Merck, Oncothyreon
Consultant: Sanofi Aventis, GlaxoSmithKline
Kevin Kim, MD Grant/Research: Genentech/Roche, Novartis
Consultant: Genentech/Roche, Novartis
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report relative to this activity.
Amit K. Verma, MB,BS Speaker's Bureau: Celgene
Grant/Research: GSK
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.
Alyce Kuklinski, NP, RN, Senior Medical Director Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, contact OMedLive at 877.394.1306 or at Support@OMedLive.com

Forgot Password Click Here to Register